
Global childhood vaccination rates plummet
Childhood vaccination rates have plummeted around the world over the last two decades leaving millions of children vulnerable to preventable diseases, according to a major study.
Although the number of vaccinated children has nearly doubled since 1980 – global polio immunisation rates, for example, rose from 42 per cent to 80 per cent – progress has stalled or even reversed in many countries since 2010.
The study, published in The Lancet, analysed coverage rates for 11 core vaccines for diseases like diphtheria, tetanus, whopping cough, and measles recommended by the World Health Organization (WHO) across 204 countries and territories.
Vaccine hesitancy, unequal access to healthcare – particularly in fragile or conflict-affected states – and the long-lasting disruptions caused by the Covid-19 pandemic, are among several factors behind the decline in coverage.
Nearly 16 million children worldwide have never received a single vaccine, more than half of whom live in just eight countries: Nigeria, India, the Democratic Republic of Congo (DRC), Ethiopia, Somalia, Sudan, Indonesia, and Brazil.
The issue is not just reserved to poorer countries – 21 out of 36 high-income countries also experienced drop in coverage for at least one dose of vaccines against diphtheria, tetanus, whooping cough, polio, or tuberculosis since 2010, mainly due to rising vaccine scepticism.
In Britain alone, measles vaccination rates have fallen to their lowest levels since the 1990s, with only 85 per cent of children under five fully protected, whilst whooping cough vaccination among pregnant women also declined from 70 per cent in 2017 to 58 per cent in 2023.
Globally, the proportion of children receiving the measles vaccine declined in 100 of 204 countries since 2010, with the largest decrease observed in Latin America and the Caribbean, where coverage fell from around 90 per cent in 2010 to 87 per cent 2019, resulting in almost one million fewer children being vaccinated against measles.
The pandemic greatly exacerbated challenges with global vaccination rates, which saw a sharp beginning in 2020 – resulting in an estimated 15.6 million children missing the full three doses of the diphtheria-tetanus-pertussis vaccine or a measles vaccine between 2020 and 2023, as well as 15.9 million children not receiving any polio vaccine, and 9.18 million missing out on the tuberculosis vaccine.
Increased risk of vaccine-preventable disease
The decline in global immunisation coverage has resulted in a significant rise in the number of vaccine-preventable disease outbreaks in recent years, the authors said.
Pakistan and Afghanistan reported 74 and 23 cases of wild polio virus in 2024, more than a four-fold increase from the year before.
Papua New Guinea, where less than half the population is vaccinated, is also experiencing its first polio outbreak since 2018.
In 2024, the European Union reported 32,265 cases of measles compared to just 3,973 in 2023 – a jump of more than a factor of 10 – while an ongoing measles outbreak in the southern states of the US has resulted in over 1,000 cases and two deaths so far in 2025, already surpassing the number of total cases recorded in 2024.
The authors say that the global immunisation targets set by the WHO for 2030 – that more than 90 per cent should be fully vaccinated against measles, diphtheria, tetanus, pertussis, and pneumococcal disease – will not be reached without 'transformational improvements,' including efforts to tackle vaccine disinformation and the strengthening of healthcare systems to reach the most vulnerable.
'Despite the monumental efforts of the past 50 years, progress has been far from universal. Large numbers of children remain under- and un-vaccinated', said senior study author Dr Jonathan Mosser from the Institute for Health Metrics and Evaluation (IHME), University of Washington.
'Routine childhood vaccinations are among the most powerful and cost-effective public health interventions available, but persistent global inequalities, challenges from the Covid pandemic, and the growth of vaccine misinformation and hesitancy have all contributed to faltering immunisation progress.
'These trends increase the risk of outbreaks of vaccine-preventable diseases, including measles, polio, and diphtheria, underscoring the critical need for targeted improvements to ensure that all children can benefit from lifesaving immunisations,' Dr Mosser added.
The findings come ahead of a pledge summit for Gavi, The Vaccine Alliance on Wednesday, in which the organisation – which facilitates vaccinations for half the world's children against some of the world's deadliest diseases – is seeking to secure $9 billion in order to immunise 500 million children over the next few years.
The Gates Foundation on Tuesday said it would commit $1.6 billion over the next five years to support Gavi, but said that the money would not be enough to plug the gaps left by rich nations if they reduce their commitments.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
3 hours ago
- Daily Mail
Tragedy as young boy dies after catching a routine flu leaving family shocked: 'He fought hard to the very last minute'
The grieving family of an 11-year-old boy have shared a touching tributes online after the 'much loved' schoolboy died after catching a 'routine flu '. Mateo Deveraturda, 11, from Napier - a coastal city on New Zealand 's North Island - showed signs of a common flu. However, on June 10, his condition worsened prompting his parents to take him to the doctors. Mateo was immediately transferred to Hastings Hospital before being airlifted to Starship Children's Hospital in Auckland - some 425km away - later that night. Doctors put Mateo in an induced coma but the young boy suffered multiple organ failure. In an online appeal, Mateo's family explained 'what began as a routine flu that quickly escalated into a life-threatening situation'. 'Once a vibrant, energetic child, Mateo's sudden decline has left his family in shock and heartache,' they wrote. 'His parents and two brothers remain by his side, navigating this overwhelming journey with unwavering love and hope.' However, despite the tireless efforts of the medical team, Mateo's condition had significantly declined. On Tuesday, the family explained Mateo was 'no longer responding treatment' and the dialysis was no longer working. 'After many difficult conversations and with heavy hearts, his doctors, nurses, and family have made the hard decision to let Mateo rest, allowing him to choose when he himself is to tired and ready to leave earth,' the family wrote. In a post shared to Facebook on Wednesday, Mateo's school revealed their 'much loved' student had died. 'It is with deep sadness that we share the news that our much-loved St Joseph student, Mateo, has passed away,' St Patrick's School in Napier wrote. 'After becoming very unwell, Mateo was taken to Starship Hospital, where he was surrounded by love and care. 'Our thoughts and prayers are with his whanau at this time. We also hold his little brother, Montiel (in our Angel whanau) especially close in our hearts. 'As a faith-filled school, we believe in the promise of eternal life and the love of God, even in the midst of our sadness. 'We ask our community to please pray Mateo's family, his friends, and all those who loved him. 'This is a time to come together, to support one another, and to show compassion. Please reach out if your child or family needs support - we are here for you.' His father Brian Deveraturda also shared a touching tribute on Facebook, describing his son as fighting 'hard to the very last minute'. 'I regret to inform everyone that our son Mateo has left us to be on our Creator's side,' Mr Deveraturda wrote. 'He fought hard to the very last minute, his spirit still wanted to keep fighting but his earthly body has given up. 'Rest in peace my son, fly high... I love you so much my son and the heaven has gained a new angel.' Mateo's older brother Miguel also shared a heartbreaking message, wishing that the two 'could have grown up together'. 'I still can't accept how I was right next to you a couple weeks ago eating dinner/ You were trying hard to use chop sticks to eat your noodles and you were struggling,' Miguel wrote. 'I will always remember our last fist bump and hug. Mate, you will always be in my heart, I really wish we could have grown up together.'


BBC News
3 hours ago
- BBC News
Lateral flow test could save people from deadly fungal infection
A new test which creators say could one day save the lives of people suffering from a deadly fungal infection is being developed at the University of commonly known as black fungus disease, spiked during the second wave of the Covid-19 pandemic. Now, Professor Chris Thornton, a professor in fungal immunology at the university, has developed a prototype lateral flow test, which could save valuable time in getting patients the treatment they test has been validated using patient samples could be ready to use in hospitals within three years if it passes regulatory checks, project leaders said. The fugal spores that cause black fungus disease are ever-present in the environment and harmless for most people. The disease is rare and thought to only affect those with compromised immunity. However, a combination of Covid infection, poorly-managed diabetes and an over-use of steroids to control lung inflammation from Covid led to a spike in infections. In 2021, there was an epidemic in India, with 40,000 cases leading to 3,500 deaths. Many of the survivors were left with facial still at prototype stage, a new study published in the Journal of Clinical Microbiology has shown the new test to be swift and accurate in identifying the disease. Professor Thornton, co-author of the study, said: "Mucormycosis is an horrific disease, which spreads rapidly in the body and can leave people horribly facially disfigured, and is often fatal.""Early diagnosis is crucial for the best outcome. This study shows that our new test is quick and effective. "These exciting results are a critical milestone in the development and validation of the test, which we aim to commercialise in the next three years." The study was conducted in partnership with colleagues at Besançon University hospital in France. Researchers tested the device in patients with mucormycosis, patients with other fungal infections, and patients without fungal infections. The test detects mucormycosis in 30 minutes with a high level of specificity and sensitivity.


The Independent
8 hours ago
- The Independent
Mother's delight as gene therapy offers hope to three-year-old
A child with a life-threatening disease has become the youngest in the UK to receive a groundbreaking gene therapy. Three-year-old Gunreet Kaur has a rare inherited condition that affects children's physical, mental and behavioural development. Children with aromatic l-amino acid decarboxylase (AADC) deficiency find it difficult to control their head, blood pressure and heart rate. But after receiving the new gene therapy, called Upstaza, Gunreet has made progress that her mother thought would never be possible, such as new movements and vocalising. It is hoped that she will make further strides as she ages. Gunreet, from Hayes in west London, was nine months old when she was diagnosed with the condition. She received the treatment in February 2024 at the world-renowned Great Ormond Street children's hospital (GOSH), which is the only hospital in the UK offering the treatment to children. Sandeep Kaur said Gunreet has made 'great progress' since her treatment. 'When Gunreet was about seven months old I noticed she wasn't reaching her milestones at the same age that her older brother did,' she said. 'She couldn't hold her own head up or reach out for items. She cried a lot and always wanted to be held. 'Since having the gene therapy, Gunreet has made great progress. 'She cries less, smiles more, and can reach for objects. 'She can hold her head up and is trying to sit up, she's recently learned how to roll from her stomach to her back which is fantastic to see. 'It means a lot to me that Gunreet was able to have this gene therapy – her general health has improved, she has more co-ordination, she can bring her palms together and is able to move her hand to her mouth.' AADC deficiency is caused by a mutation in the gene that produces the AADC enzyme, this enzyme is needed to produce a neurotransmitter called dopamine which is important in controlling movement. People with AADC deficiency do not have a working version of the enzyme, which means that they have little or no dopamine in the brain. This means that they can suffer developmental delays, weak muscle tone and inability to control the movement of the limbs. It can also lead to painful episodes for affected children. The condition is rare and often deadly, with many children with AADC deficiency not reaching adulthood. The medicine, also known as eladocagene exuparvovec, consists of a virus that contains a working version of the AADC gene. The treatment is delivered by millimetre precision to an exact location in the brain of the patient by a team of medics assisted by a robotic surgery tool. When given to the patient, it is expected that the virus will carry the AADC gene into nerve cells, enabling them to produce the missing enzyme. This is expected to enable the cells to produce the dopamine they need to work properly, which will improve symptoms of the condition. It is the first NHS England commissioned gene therapy in the UK infused directly into the brain. Professor Manju Kurian, consultant paediatric neurologist at GOSH, said 'AADC deficiency is a rare condition but often a cruel one that has such a profound impact on children and their carers and families. 'We know children with the condition have painful episodes that can last for hours and, as their condition progresses, their life becomes more and more difficult. 'It's incredible to me that I can now prescribe novel gene therapies just as I would prescribe paracetamol and antibiotics. 'While the treatment is now available under the NHS at GOSH, we can only do this by working collaboratively across teams inside and outside the hospital, from physios and surgeons to dietitians and speech therapists, alongside partnerships with companies who supply these therapies. 'It's great to see how this treatment has been able to help babies and children across the country like Gunreet. 'The natural history of the condition is that most patients cannot fully hold their head or make any developmental progress after that milestone. 'Gunreet's progress over the last year has been really impressive in that context, as well as the virtual disappearance of the eye crises. 'We're hopeful that one day she will be able to talk or walk, as seen in some of the young patients treated in the clinical trial.' Professor James Palmer, NHS medical director for specialised commissioning, said: 'This is wonderful news for Gunreet and her family, and a powerful example of how these commitments are translating into real improvements in people's lives. 'By bringing cutting-edge medicines like eladocagene exuparvovec into the health service and setting up our expert clinical teams to successfully deliver them, the NHS is making clear its commitment to improving care through innovation.'